ClinicalTrials.gg
CompletedNCT00623597Updated Mar 7, 2016Results posted

A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.

A Phase 2 interventional study of ritonavir and saquinavir [Invirase] in HIV Infections, sponsored by Hoffmann-La Roche. Completed at 10 sites in 3 countries. Open to participants aged 4 Months to 6 Years. Per ClinicalTrials.gov, last updated 2016-03-07.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
4 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 124 studies testing ritonavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Ritonavir · HIV Infections.

Enrollment
98th of 119
18 · median 46
Started
2008
with 9 others
Phase 2
31 of 124
none open now
Registered
81st of 124
by date
Lead sponsor
7 of 124
Hoffmann-La Roche

Among the 124 studies testing ritonavir in HIV Infections, this one is the 98th largest by enrollment of the 119 interventional ones that give a count, is one of 10 that started in 2008, is one of 31 in phase 2, and was the 81st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 124 studies testing ritonavir in HIV Infections is open now. Recruiting first, the newest first:

About ritonavir

Ritonavir: first FDA approval 1996 (NORVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 4 Months to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 124 studies testing ritonavir in HIV Infections, or all of them as a file.
02

Study summary

This single arm study will assess the pharmacokinetics, safety and activity of saquinavir (Invirase hard gel capsules, film coated tablets or opened capsules) boosted by combination with ritonavir, in HIV-1 infected infants and children between the ages of 4 months and 6 years. Patients will commence treatment with saquinavir 50mg/kg bid plus ritonavir 2.5mg/kg or 3.0mg/kg (dependent on body weight), and a background antiretroviral regimen. If drug exposures are found to be dissimilar to those previously seen in older children and adults, or are associated with toxicities, subsequent dose adjustments will be made. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
4 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infants and children, 4 months to \<6 years;
  • confirmed -1 infection;
  • patients for whom saquinavir/ritonavir together with >=2 background ARVs is considered appropriate.

Exclusion criteria

Exclusion Criteria:

  • body weight >4kg/8.8 pounds;
  • use of any concomitant medications that may interfere with the pharmacokinetics of saquinavir or ritonavir;
  • malabsorption, severe chronic diarrhea or vomiting within 28 days of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    1

    Drug: ritonavir · Drug: saquinavir [Invirase]

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma Trough Concentrations (Ctrough) for Saquinavir

    Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Saquinavir was normalized to a dose of 50 mg/kg.

    Time frame: Pre-dose at Weeks 8, 12, 24.

  2. Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir

    The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of saquinavir was normalized to a dose of 50 mg/kg.

    Time frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an Non-nucleoside reverse transcriptase inhibitor [NNRTI] containing regimen).

  3. Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes

    Time frame: From Baseline (Day 1) till Week 48 and Follow-up (Week 52)

  4. Change In Hematocrit From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  5. Change In Hemoglobin, Total Protein And Total Albumin From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  6. Change In White Blood Cell (WBC), Platelet, Basophil, Lymphocyte, Monocyte, Neutrophil And Eosinophil Cell Counts From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  7. Change In Red Blood Cell (RBC) Counts From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  8. Change In Creatine Kinase (CK), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alkaline Phosphatase (ALP), Serum Glutamic-Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) Counts From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  9. Change In Total Bilirubin, Creatinine, Uric Acid From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  10. Change In Blood Urea Nitrogen (BUN), Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL Cholesterol), Triglycerides, Calcium, Potassium, Sodium, Chloride, Phosphate, Fasting Glucose From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  11. Change In Hematuria, Glycosuria And Proteinuria From Baseline

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

Secondary outcomes

  1. Plasma Trough Concentrations (Ctrough) for Ritonavir

    Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Ritonavir was normalized to a dose of 100 mg/kg.

    Time frame: Pre-dose at Weeks 8, 12, 24

  2. Maximum Observed Concentration (Cmax) for Saquinavir and Ritonavir

    The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was normalized to a dose of 50 mg/kg for Saquinavir and100 mg/kg for Ritonavir.

    Time frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen and at Week 24

  3. Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir

    The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of ritonasvir was normalized to a dose of 100 mg/kg.

    Time frame: Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen).

  4. Change From Baseline in Mean Human Immunodeficiency Virus Viral Load

    Change from baseline in plasma HIV-1 RNA was derived as Change from baseline = Log10 (HIV-1 RNA at week x) - Log10 (HIV-1 RNA at baseline)

    Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.

  5. Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <400 Copies/mL

    The number of participants with HIV-1 RNA results \<400 copies/mL were reported

    Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.

  6. Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <50 Copies/mL

    The number of participants with HIV-1 RNA results \<50 copies/mL were reported.

    Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.

  7. Number of Participants With >1 Log Decrease From Baseline in Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA )

    The number of participants experiencing a greater than 1 log drop from baseline (day 1) (log 10 transformed) were reported

    Time frame: From Week 8 till Week 48

  8. Number of Participants With Virological Failure

    Virological failure was defined as: viral load \>= 400 copies/mL on two consecutive occasions (missing visits was assumed to be above 400 copies/mL). The number of participants classified as virological failure by Age Group and viral load (≤ 10,000 copies, \>10,000 copies) were presented.

    Time frame: From Week 12 till Week 48

  9. Change From Baseline in Cluster Differentiation Antigen 4 (CD4) Lymphocyte Count

    Change from Baseline in CD4+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD4+ lymphocyte count was derived as follows: Change from baseline = (CD4+ count at week 24/48) - (CD4+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.

    Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation

  10. Change From Baseline in Cluster Differentiation Antigen 8 (CD8) Lymphocyte Count

    Change from baseline in CD8+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD8+ lymphocyte count was derived as follows: Change from baseline = (CD8+ count at week 24/48) - (CD8+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.

    Time frame: Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation

07

Results

Posted Jan 14, 2016

Participant flow

A total of 18 participants were recruited from 8 centers in Argentina (3 centers), Spain (1 center) and Thailand (4 centers). This study was conducted between May 20, 2008 and March 11, 2010.

Participant flow — Overall Study
MilestoneGroup AGroup B
Started513
Completed413
Not completed10
Withdrew: Failed to return10

Outcome measures

PrimaryPlasma Trough Concentrations (Ctrough) for Saquinavir

Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Saquinavir was normalized to a dose of 50 mg/kg.

Time frame:
Pre-dose at Weeks 8, 12, 24.
Reported as:
Mean · ng/mL
Plasma Trough Concentrations (Ctrough) for Saquinavir
ng/mLGroup AGroup B
Plasma Trough Concentrations (Ctrough) for Saquinavir645 ± 5361860 ± 1060
PrimaryArea Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir

The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of saquinavir was normalized to a dose of 50 mg/kg.

Time frame:
Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an Non-nucleoside reverse transcriptase inhibitor [NNRTI] containing regimen).
Reported as:
Mean · h*ug/mL
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir
h*ug/mLGroup AGroup B
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Saquinavir18.7 ± 20.038 ± 18.1
PrimaryIncidence of Adverse Events (AE) and Serious Adverse Events (SAE)

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes

Time frame:
From Baseline (Day 1) till Week 48 and Follow-up (Week 52)
Reported as:
Number · participants
Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)
participantsGroup AGroup BTotal
Any serious adverse events123
Any non-serious adverse events5914
PrimaryChange In Hematocrit From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · fraction
Change In Hematocrit From Baseline
fractionGroup AGroup BTotal
Change from Baseline at Week 24 (n= 4, 13, 17)0.01 ± 0.011-0 ± 0.03-0 ± 0.027
Change from Baseline at Week 48 (n= 4, 13, 17)0.03 ± 0.037-0.01 ± 0.0440 ± 0.044
SecondaryPlasma Trough Concentrations (Ctrough) for Ritonavir

Plasma trough concentration is the average steady state concentration prior to morning and evening dose. Ctrough of Ritonavir was normalized to a dose of 100 mg/kg.

Time frame:
Pre-dose at Weeks 8, 12, 24
Reported as:
Mean · ng/mL
Plasma Trough Concentrations (Ctrough) for Ritonavir
ng/mLGroup AGroup B
Plasma Trough Concentrations (Ctrough) for Ritonavir577 ± 366995 ± 548
SecondaryMaximum Observed Concentration (Cmax) for Saquinavir and Ritonavir

The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration. Cmax was normalized to a dose of 50 mg/kg for Saquinavir and100 mg/kg for Ritonavir.

Time frame:
Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen and at Week 24
Reported as:
Mean · ng/mL
Maximum Observed Concentration (Cmax) for Saquinavir and Ritonavir
ng/mLGroup AGroup B
Saquinavir2910 ± 31105570 ± 2780
Ritonavir2050 ± 12703370 ± 2020
SecondaryArea Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir

The area under the plasma concentration-time curve from time zero to twelve hours (AUC0-12h) is area under the plasma concentration-time curve from time zero through actual tlast. The area under the plasma concentration-time curve from time zero to twelve hours of ritonasvir was normalized to a dose of 100 mg/kg.

Time frame:
Pre-dose and 3, 4, 8, 12 hours (post-dose) on Day 14 (± 2 days), or Day 28(+ 2 days) for patients switching from an NNRTI containing regimen).
Reported as:
Mean · h*ug/mL
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir
h*ug/mLGroup AGroup B
Area Under the Plasma Concentration-time Curve Over the Time Interval From Zero to Twelve Hours (AUC0-12h) for Ritonavir13.6 ± 8.1821.8 ± 11.6
SecondaryChange From Baseline in Mean Human Immunodeficiency Virus Viral Load

Change from baseline in plasma HIV-1 RNA was derived as Change from baseline = Log10 (HIV-1 RNA at week x) - Log10 (HIV-1 RNA at baseline)

Time frame:
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Reported as:
Mean · log10 copies/mL
Change From Baseline in Mean Human Immunodeficiency Virus Viral Load
log10 copies/mLGroup AGroup BTotal
Change from Baseline at Week 24 (n= 3, 13, 16)-0.75 ± 1.48-1.81 ± 1.57-1.61 ± 1.57
Change from Baseline at Week 48 (n= 3, 13, 16)-1.27 ± 1.01-1.39 ± 1.53-1.36 ± 1.42
SecondaryNumber of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <400 Copies/mL

The number of participants with HIV-1 RNA results \<400 copies/mL were reported

Time frame:
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Reported as:
Number · participants
Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <400 Copies/mL
participantsGroup AGroup BTotal
Baseline (n= 5, 13, 18)156
Week 24 (n= 3, 13, 16)21315
Week 48 (n= 3, 13, 16)21113
SecondaryNumber of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <50 Copies/mL

The number of participants with HIV-1 RNA results \<50 copies/mL were reported.

Time frame:
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 (or upon premature discontinuation); a baseline collection was made if there was not already a value available taken within the previous 4 weeks.
Reported as:
Number · participants
Number of Participants With Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA) <50 Copies/mL
participantsGroup AGroup BTotal
Baseline (n= 5, 13, 18)044
Week 24 (n= 3, 13, 16)21113
Week 48 (n= 3, 13, 16)2911
SecondaryNumber of Participants With >1 Log Decrease From Baseline in Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA )

The number of participants experiencing a greater than 1 log drop from baseline (day 1) (log 10 transformed) were reported

Time frame:
From Week 8 till Week 48
Reported as:
Number · participants
Number of Participants With >1 Log Decrease From Baseline in Human Immunodeficiency Virus (HIV) -Ribonucleic Acid (RNA )
participantsGroup AGroup BTotal
Week 8 (n= 4, 12, 16)178
Week 24 (n= 3, 13, 16)189
Week 48 (n= 3, 13, 16)178
SecondaryNumber of Participants With Virological Failure

Virological failure was defined as: viral load \>= 400 copies/mL on two consecutive occasions (missing visits was assumed to be above 400 copies/mL). The number of participants classified as virological failure by Age Group and viral load (≤ 10,000 copies, \>10,000 copies) were presented.

Time frame:
From Week 12 till Week 48
Reported as:
Number · participants
Number of Participants With Virological Failure
participantsGroup AGroup BTotal
VF at Week 12 (n= 5, 13, 18)213
VF at Week 24 (n= 5, 13, 18)202
VF at Week 48 (n= 5, 13, 18)314
HIV-RNA <= 10,000 copies/mL at Wk 12 (n= 3, 6, 9)101
HIV-RNA <= 10,000 copies/mL at Wk 24 (n= 3, 6, 9)101
HIV-RNA <= 10,000 copies/mL at Wk 48 (n= 3, 6, 9)202
HIV-RNA >10,000 copies/mL at Week 12 (n= 2, 7, 9)112
HIV-RNA >10,000 copies/mL at Week 24 (n= 2, 7, 9)101
HIV-RNA >10,000 copies/mL at Week 48 (n= 2, 7, 9)112
SecondaryChange From Baseline in Cluster Differentiation Antigen 4 (CD4) Lymphocyte Count

Change from Baseline in CD4+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD4+ lymphocyte count was derived as follows: Change from baseline = (CD4+ count at week 24/48) - (CD4+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.

Time frame:
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
Reported as:
Mean · count/uL
Change From Baseline in Cluster Differentiation Antigen 4 (CD4) Lymphocyte Count
count/uLGroup AGroup BTotal
Change from Baseline at Week 24 (n= 3, 12, 15)94.90 ± 643.28-34.53 ± 821.31-8.65 ± 769.41
Change from Baseline at Week 48 (n= 3, 12, 15)-50.07 ± 1013.23126.11 ± 528.4990.87 ± 609.46
SecondaryChange From Baseline in Cluster Differentiation Antigen 8 (CD8) Lymphocyte Count

Change from baseline in CD8+ lymphocyte count at 24 weeks and 48 weeks were presented by age group. Change from baseline in CD8+ lymphocyte count was derived as follows: Change from baseline = (CD8+ count at week 24/48) - (CD8+ count at baseline). A baseline collection was made if there was not already a value available taken within the previous 4 weeks. Baseline was on Day 1.

Time frame:
Baseline (Day 1), Weeks 8, 12, 24, 36, and 48 or upon premature discontinuation
Reported as:
Mean · count/uL
Change From Baseline in Cluster Differentiation Antigen 8 (CD8) Lymphocyte Count
count/uLGroup AGroup BTotal
Change from Baseline at Week 24 (n= 3, 12, 15)-200.49 ± 161.05-3.50 ± 790.86-42.90 ± 708.37
Change from Baseline at Week 48 (n= 3, 12, 15)-92.07 ± 455.2340.52 ± 641.2714.00 ± 596.43
PrimaryChange In Hemoglobin, Total Protein And Total Albumin From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · g/L
Change In Hemoglobin, Total Protein And Total Albumin From Baseline
g/LGroup AGroup BTotal
Hemoglobin, Change from BL at Wk 24 (n= 4, 13, 17)-0 ± 3.31 ± 12.11 ± 10.6
Hemoglobin, Change from BL at Wk 48 (n= 4, 13, 17)6 ± 11.80 ± 14.42 ± 13.7
Total Protein, Change from BL at Wk 24 (n=4,13,17)-4 ± 6.02 ± 12.60 ± 11.5
Total Protein, Change from BL at Wk 48 (n=4,13,17)-5 ± 5.7-0 ± 14.3-1 ± 12.8
Total Albumin, Change from BL at Wk 24 (n=4,13,17)0.5 ± 5.415 ± 7.684 ± 7.32
Total Albumin, Change from BL at Wk 48 (n=4,13,17)1.3 ± 2.294 ± 8.73.4 ± 7.7
PrimaryChange In White Blood Cell (WBC), Platelet, Basophil, Lymphocyte, Monocyte, Neutrophil And Eosinophil Cell Counts From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · 10*9/L
Change In White Blood Cell (WBC), Platelet, Basophil, Lymphocyte, Monocyte, Neutrophil And Eosinophil Cell Counts From Baseline
10*9/LGroup AGroup BTotal
WBC, Change from BL at Wk 24 (n= 4,13,17)-3 ± 2.31-1 ± 4.35-1.5 ± 4.0
WBC, Change from BL at Wk 48 (n= 4,13,17)-2.1 ± 1.72-0.9 ± 4.38-1.2 ± 3.9
Platelet, Change from BL at Wk 24 (n= 4,13,17)-119 ± 93.424 ± 148.9-9 ± 148.9
Platelet, Change from BL at Wk 48 (n= 4,13,17)-50 ± 130.4-2 ± 118.9-13 ± 119.3
Basophil, Change from BL at Wk 24 (n=4 ,13,17)-0.02 ± 0.0280 ± 0.031-0.01 ± 0.031
Basophil, Change from BL at Wk 48 (n=4 ,13,17)-0 ± 0.03-0.01 ± 0.029-0.01 ± 0.028
Lymphocyte, Change from BL at Wk 24 (n=2, 2, 4)-0.9 ± 0.3-1.1 ± 1.20-1 ± 0.72
Lymphocyte, Change from BL at Wk 48 (n= 2, 2, 4)-1.5 ± 0.29-0.7 ± 1.05-1.1 ± 0.76
Monocyte, Change from BL at Wk 24 (n= ,13,17)-0.41 ± 0.295-0.01 ± 0.361-0.11 ± 0.379
Monocyte, Change from BL at Wk 48 (n= ,13,17)-0.21 ± 0.179-0.05 ± 0.384-0.09 ± 0.348
Neutrophil, Change from BL at Wk 24 (n=2, 2, 4)-1.4 ± 0.33-2.8 ± 1.87-2.1 ± 1.36
Neutrophil, Change from BL at Wk 48 (n= 2, 2, 4)-1.7 ± 1.15-1.6 ± 2.55-1.6 ± 1.62
Eosinophil, Change from BL at Wk 24 (n=2, 2, 4)-0 ± 0.2-0 ± 0.1-0 ± 0.1
Eosinophil, Change from BL at Wk 48 (n= 2, 2, 4)-0 ± 0.20 ± 1.10 ± 0.7
PrimaryChange In Red Blood Cell (RBC) Counts From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · 10*12/L
Change In Red Blood Cell (RBC) Counts From Baseline
10*12/LGroup AGroup BTotal
RBC,Change from Baseline at Week 24 (n= 4, 13, 17)-0.18 ± 0.227-0.07 ± 0.673-0.1 ± 0.593
RBC,Change from Baseline at Week 48 (n= 4, 13, 17)0.02 ± 0.125-0.16 ± 0.74-0.12 ± 0.648
PrimaryChange In Creatine Kinase (CK), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alkaline Phosphatase (ALP), Serum Glutamic-Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) Counts From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · U/L
Change In Creatine Kinase (CK), Serum Glutamic Oxaloacetic Transaminase (SGOT), Alkaline Phosphatase (ALP), Serum Glutamic-Pyruvic Transaminase (SGPT), Gamma-Glutamyl Transferase (GGT) Counts From Baseline
U/LGroup AGroup BTotal
CK, Change from Baseline at Week 24 (n= 3, 3, 16)112 ± 112.0-12 ± 115.911 ± 122.2
CK, Change from Baseline at Week 48 (n= 3, 3, 16)257 ± 244.8-7 ± 8443 ± 158
SGOT, Change from Baseline at Week 24 (n= 4,13,17)-0 ± 1.5-0 ± 8.2-0 ± 7.1
SGOT, Change from Baseline at Week 48 (n= 4,13,17)-1 ± 7.8-0 ± 6.9-0 ± 6.8
ALP, Change from Baseline at Week 24 (n=4, 12, 16)10 ± 29.826 ± 23.222 ± 24.9
ALP, Change from Baseline at Week 48 (n=4, 12, 16)47 ± 87.636 ± 26.539 ± 45.6
SGPT, Change from Baseline at Week 24 (n=4,13,17)-9 ± 15.3-2 ± 13.6-4 ± 13.8
SGPT, Change from Baseline at Week 48 (n=4,13,17)-2 ± 13.4-3 ± 12.1-3 ± 12
GGT, Change from Baseline at Week 24 (n=4, 13, 17)5 ± 4.7-7 ± 18.7-4 ± 17.1
GGT, Change from Baseline at Week 48 (n=4, 13, 17)5 ± 2.1-5 ± 18.5-2 ± 16.7
PrimaryChange In Total Bilirubin, Creatinine, Uric Acid From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · umol/L
Change In Total Bilirubin, Creatinine, Uric Acid From Baseline
umol/LGroup AGroup BTotal
Total Bilirubin-Change from BL at Wk 24(n=4,12,16)2 ± 2.82 ± 5.52 ± 4.9
Total Bilirubin-Change from BL at Wk 48(n=4,12,16)1 ± 1.12 ± 6.91 ± 5.9
Cretainine- Change from BL at Wk 24 (n=4, 13,17)-2 ± 6.73 ± 102 ± 9.5
Cretainine- Change from BL at Wk 48 (n=4, 13,17)3 ± 10.75 ± 9.25 ± 9.3
Uric acid- Change from BL at Wk 24 (n=4, 13,17)-27 ± 54.368 ± 55.146 ± 67.6
Uric acid- Change from BL at Wk 48 (n=3,13,16)-42 ± 108.461 ± 63.541 ± 80.6
PrimaryChange In Blood Urea Nitrogen (BUN), Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL Cholesterol), Triglycerides, Calcium, Potassium, Sodium, Chloride, Phosphate, Fasting Glucose From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · mmol/L
Change In Blood Urea Nitrogen (BUN), Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL Cholesterol), Triglycerides, Calcium, Potassium, Sodium, Chloride, Phosphate, Fasting Glucose From Baseline
mmol/LGroup AGroup BTotal
BUN,Change from Baseline at Week 24 (n= 3, 13, 16)-1.5 ± 2.781 ± 2.20.5 ± 2.43
BUN,Change from Baseline at Week 48 (n= 3, 13, 16)0.4 ± 0.661.1 ± 2.00.9 ± 1.82
LDL,Change from Baseline at Week 24 (n= 3, 13, 16)0.21 ± 0.2370.21 ± 1.3890.21 ± 1.245
LDL,Change from Baseline at Week 48 (n= 3, 13, 16)0.23 ± 0.596-0.11 ± 1.038-0.04 ± 0.963
HDL,Change from Baseline at Week 24 (n= 3, 13, 16)0.21 ± 0.2020.13 ± 0.3690.15 ± 0.34
HDL,Change from Baseline at Week 48 (n= 3, 13, 16)0.41 ± 0.2330.17 ± 0.3870.21 ± 0.37
Triglyceride,Change from BL at Wk 24 (n=4,13, 17)-0.28 ± 0.597-0.19 ± 1.376-0.21 ± 1.22
Triglyceride,Change from BL at Wk 48 (n=4,13, 17)-0.19 ± 0.496-0.15 ± 1.558-0.16 ± 1.366
Calcium,Change from BL at Wk 24 (n=2, 12, 14)-0.15 ± 0.040.15 ± 0.170.11 ± 0.19
Calcium,Change from BL at Wk 48 (n=2, 12, 14)-0.16 ± 0.090.09 ± 0.170.06 ± 0.18
Potassium,Change from BL at Wk 24 (n=4,13, 17)-0.1 ± 0.16-0.3 ± 0.63-0.2 ± 0.56
Potassium,Change from BL at Wk 48 (n=4,13, 17)0.2 ± 0.59-0.2 ± 0.54-0.1 ± 0.57
Sodium,Change from BL at Wk 24 (n=4,13, 17)2 ± 1.3-1 ± 2.3-0 ± 2.3
Sodium,Change from BL at Wk 48 (n=4,13, 17)1 ± 2.2-1 ± 3.8-0 ± 3.5
Chloride,Change from BL at Wk 24 (n=4,13, 17)-1 ± 2.8-2 ± 4.2-2 ± 3.9
Chloride,Change from BL at Wk 48 (n=4,13, 17)1 ± 1.3-2 ± 3.6-1 ± 3.3
Phosphate,Change from BL at Wk 24 (n=2, 12, 14)-0.02 ± 0.1140.17 ± 0.1880.14 ± 0.188
Phosphate,Change from BL at Wk 48 (n=2, 13, 15)-0.26 ± 0.00.12 ± 0.2120.07 ± 0.237
Fasting Glucose,Change from BL at Wk 24(n=4,13,17)-0.26 ± 0.9630.02 ± 1.253-0.05 ± 1.169
Fasting Glucose,Change from BL at Wk 48(n=4,13,17)-0.07 ± 0.8570.14 ± 1.5370.09 ± 1.385
PrimaryChange In Hematuria, Glycosuria And Proteinuria From Baseline

Change from Baseline was calculated as the post-Baseline value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · [0 to 4+]
Change In Hematuria, Glycosuria And Proteinuria From Baseline
[0 to 4+]Group AGroup BTotal
Hematuria-Change from BL at Wk 24 (n= 1, 2, 3)0 ± 00 ± 00 ± 0
Hematuria-Change from BL at Wk 48 (n= 1, 2, 3)0 ± 00 ± 00 ± 0
Glycosuria-Change from BL at Wk 24 (n= 1, 2, 3)0 ± 00 ± 00 ± 0
Glycosuria-Change from BL at Wk 48 (n= 1, 2, 3)0 ± 00 ± 00 ± 0
Proteinuria-Change from BL at Wk 24 (n= 1, 2, 3)0 ± 00 ± 00 ± 0
Proteinuria-Change from BL at Wk 48 (n= 1, 2, 3)0 ± 00 ± 00 ± 0

Adverse events

Collected over Up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A—1/5 (20%)5/5 (100%)
Group B—2/13 (15.4%)9/13 (69.2%)
Total—3/18 (16.7%)14/18 (77.8%)
Most frequent serious events
Most frequent serious events
EventGroup AGroup BTotal
PneumoniaInfections and infestations1/51/132/18
BronchitisRespiratory, thoracic and mediastinal disorders0/51/131/18
Most frequent other events
Showing 10 of 32
Most frequent other events
EventGroup AGroup BTotal
ConstipationGastrointestinal disorders2/50/132/18
DiarrhoeaGastrointestinal disorders0/53/133/18
Upper Respiratory Tract InfectionInfections and infestations1/51/132/18
GiardiasisInfections and infestations1/50/131/18
NasopharyngitisInfections and infestations1/50/131/18
ToxocariasisInfections and infestations1/50/131/18
VomitingGastrointestinal disorders1/52/133/18
Dental CariesGastrointestinal disorders1/52/133/18
Abdominal PainGastrointestinal disorders1/50/131/18
Gait DisturbanceGeneral disorders1/50/131/18

Baseline characteristics

The Safety Analysis Population (SAP) comprised all participants who received at least one dose of study medication. The SAP was used for all efficacy and safety analyses

Age, Continuous
Age, Continuous(years)Group AGroup BTotal
Mean0.8 ± 0.454.0 ± 1.083.1 ± 1.75
Sex: Female, Male
Sex: Female, Male(Participants)Group AGroup BTotal
Female3811
Male257
08

Study locations

10 sites
  • Buenos Aires, 1202, Argentina
  • Buenos Aires, 1425, Argentina
  • Santa Fe, 3000, Argentina
  • Madrid, 28046, Spain
  • Madrid, 28905, Spain
  • Valencia, 46009, Spain
  • Bangkok, 10400, Thailand
  • Khon Kaen, 40002, Thailand
  • Pathumwan, 10330, Thailand
  • Payathai, 10400, Thailand
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 5 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2008
First posted
Feb 26, 2008
Start
Jun 2008
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jan 14, 2016
Last update
Mar 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00623597
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 26, 2008
Start date
Jun 2008
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jan 14, 2016
Last update
Mar 7, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ritonavir

Start the discussion